ArticleDiscover oncology2026
CCL19 and CCR6 as diagnostic biomarkers for differentiating phyllodes tumors from breast fibroadenomas: a machine learning-driven approach integrating EMT biology.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study aimed to differentiate phyllodes tumors from fibroadenomas by identifying biomarkers through bioinformatics.
methodsGene expression datasets from the GEO database were analyzed, focusing on differential expression and epithelial-mesenchymal transition (EMT)-related genes between breast fibro-ma and phyllodes tumors.
resultsA total of 209 upregulated and 254 downregulated differentially expressed genes (DEGs) were identified. Intersection with 1142 EMT genes yielded 42 EMT-DEGs. Enrichment analysis linked these genes to epithelial cell proliferation, stem cell differentiation, and activities involving collagen-containing extracellular matrices, translation, repressor activity, and mRNA post-transcriptional regulation. Hub genes were identified using Weighted Gene Co-expression Network Analysis (WGCNA), Random Forest, and Lasso regression. The genes CCL19 and CCR6 emerged as potential biomarkers and demonstrated strong internal discriminative ability between fibroadenoma and phyllodes tumor samples, with Receiver Operating Characteristic (ROC) values of 0.962 and 0.915, respectively, in the GSE78071 dataset. The combined model showed favorable internal discrimination, with a mean absolute error of 0.006. Validation with six fresh tissue specimens confirmed higher expression of CCL19 and CCR6 in fibroadenomas compared to phyllodes tumors. Further analysis revealed their roles in chemokine signaling, cytokine interactions, and signaling pathways.
conclusionCCL19 and CCR6 were identified as diagnostic biomarkers for distinguishing breast fibroadenomas from phyllodes tumors.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.